Understand the source comparison
Best Peptides for Graves Disease: Research vs Clinical Comparison
Thymalin T-regulatory cell enhancement, thymic hormone restoration Animal models show increased CD4+CD25+ Treg populations (Immunology Letters, 2009) May modulate upstream immune dysregulation driving TRAb production No human trials measuring TRAb suppression
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- T-regulatory cell enhancement, thymic hormone restoration
- Animal models show increased CD4+CD25+ Treg populations (Immunology Letters, 2009)
- May modulate upstream immune dysregulation driving TRAb production
- No human trials measuring TRAb suppression or TSH normalization
- Best evidence for immune modulation. But not a replacement for methimazole
- BPC-157
- VEGF upregulation, cytokine suppression (TNF-α, IL-6)
- Reduced systemic inflammation in animal models (J Physiol Pharmacol, 2011)
- Could reduce tissue damage from chronic hyperthyroid state
- No thyroid-specific trials; mechanism is indirect
- Supportive for inflammation. Not for antibody suppression
- KPV
- NF-κB inhibition, inflammatory gene suppression
- Reduced IL-1β and TNF-α in colitis models (Peptides, 2008)
- Potential for Graves ophthalmopathy (orbital inflammation)
- Extrapolated from non-thyroid conditions
- Plausible for ophthalmopathy. Evidence is speculative
- MK-677
- GH secretagogue, IGF-1 elevation, anabolic signaling
- Increased lean mass 1.1kg in 12-week trial (JCEM, 1998)
- Post-treatment muscle recovery after hyperthyroid wasting
- Contraindicated during active hyperthyroidism (may worsen tachycardia)
- Use only after thyroid hormones normalize
- CJC-1295/Ipamorelin
- Pulsatile GH release, mTOR pathway activation
- Preserved lean mass during caloric deficit (Growth Horm IGF Res, 2004)
- Same as MK-677. Rebuilding lost muscle post-treatment
- Same contraindication during active disease
- Effective for recovery. Not for active Graves